Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Plus Grants Program

University of Saskatchewan

$12,500.00

Developing a multi-species biofilm model for testing novel antimicrobials

FY 2017-18

Summary
Today more than ever before, new alternatives to antibiotics are needed to control infectious diseases, asimportant pathogens are becoming increasingly resistant. Microorganisms can also grow in different ways thatmakes them inherently tough to eradicate. Biofilms are a mode of growth where individual cells aggregate andbecome embedded in a resistant and protective extracellular matrix. Many livestock and human infectiousdiseases can be thought of as biofilm-related and often different microorganisms can be part of the samebiofilm. In a previous NSERC Engage grant, we worked with SterileCare Inc., a Canadian biotechnologycompany that has developed a new antimicrobial agent. In the current project, we are proposing to develop amulti-species biofilm model that more closely approximates natural conditions. Modern bacterial taggingtechnology will be used to visualize and enumerate the biofilms, and we will test the killing ability of theSterile Care product either administered alone or in concert with other non-antibiotic treatments. We willexplore the mechanisms of action of the products and work to identify treatment conditions that will lead toimproved intellectual property for the company. SterileCare Inc. hopes to further develop a powerful agent totreat both human and veterinary conditions associated with biofilms and multidrug resistant microorganisms,which falls in line with global Antibiotic Stewardship efforts.
Program
Engage Plus Grants Program
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
515729-2017
Name nom
White, Aaron
Department département
VIDO-Vaccine and Infectious Disease Organization
Organization id
16
Institution établissement
University of Saskatchewan
Province en
Saskatchewan
Province fr
Saskatchewan
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
12500
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
505
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Veterinary pharmaceuticals
Area of application fr
Produits pharmaceutiques à usage vétérinaire
Research subject code
5200
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Microbiology
Research subject fr
Microbiologie
Partie
1
Nb partie
1
Application title
Developing a multi-species biofilm model for testing novel antimicrobials
Keyword
NSERC
Application summary
Today more than ever before, new alternatives to antibiotics are needed to control infectious diseases, asimportant pathogens are becoming increasingly resistant. Microorganisms can also grow in different ways thatmakes them inherently tough to eradicate. Biofilms are a mode of growth where individual cells aggregate andbecome embedded in a resistant and protective extracellular matrix. Many livestock and human infectiousdiseases can be thought of as biofilm-related and often different microorganisms can be part of the samebiofilm. In a previous NSERC Engage grant, we worked with SterileCare Inc., a Canadian biotechnologycompany that has developed a new antimicrobial agent. In the current project, we are proposing to develop amulti-species biofilm model that more closely approximates natural conditions. Modern bacterial taggingtechnology will be used to visualize and enumerate the biofilms, and we will test the killing ability of theSterile Care product either administered alone or in concert with other non-antibiotic treatments. We willexplore the mechanisms of action of the products and work to identify treatment conditions that will lead toimproved intellectual property for the company. SterileCare Inc. hopes to further develop a powerful agent totreat both human and veterinary conditions associated with biofilms and multidrug resistant microorganisms,which falls in line with global Antibiotic Stewardship efforts.